Overview

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

Status:
Active, not recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the clinical activity of Pembrolizumab and SurVaxM in participants with recurrent glioblastoma.
Phase:
Phase 2
Details
Lead Sponsor:
David Peereboom, MD
Manmeet Ahluwalia, MD
Treatments:
Pembrolizumab
Sargramostim